Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial

By afschroeder • April 3, 2026

Ells Z, Meyer C, Kimura K, Wilhalme H, Cao M, Ludwig VB, Unterrainer LM, Sennung D, Nabong R, Felix C, Valle LF, Daley A, Czernin J, Dahlbom M, Kishan AU, Calais J. Dosimetry Analysis of ¹⁷⁷Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial. J Nucl Med. 2026 Apr 2:jnumed.125.271467. doi: 10.2967/jnumed.125.271467. Epub ahead of print. PMID: 41927282.

Tags: 177Lu, 177Lu-PSMA-I&T, Cardiology/Epi, DOM STAT, dosimetry, General Internal Medicine, oligorecurrent, prostate cancer, PSMA, Publications, SBRT, theranostics

Related Posts

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]

Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction

Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, Pandey A, Derington CG, Zheutlin AR, Fang J, Stehlik J, Fonarow GC, Bress[...]

The Importance of Genetic Testing in the Diagnosis and Management of Peripartum Cardiomyopathy: A Case Study

D'Costa ZU, Wong EK, Zhang M, Fishbein GA, Wang J, Kamath M, Shahandeh N. The Importance of Genetic Testing in the Diagnosis and Management of[...]